Potential to Prevent and Treat a Common Type of Inflammatory Arthritis Advanced by the Identification of New Genetic Links

In a first-of-its-kind genome-wide association study (GWAS) researchers have discovered two genes, RNF144B and ENPP1, that cause calcium pyrophosphate deposition (CPPD) disease in Americans of European and African descent. This crystalline arthritis is caused by calcium pyrophosphate (CPP) crystal deposition in joints. The findings of this novel study opens in new tab/window in the Annals of the Rheumatic Diseases opens in new tab/window, published by Elsevier, open up promising new avenues for targeted prevention and treatment of CPPD disease, which are currently lacking.

Characterized by the deposition of CPP crystals in articular tissues, CPPD disease is a heterogeneous crystalline arthritis that can cause acute or chronic joint symptoms and is one of the most common forms of inflammatory arthritis in individuals over 60 years of age. In Europe and North America, the prevalence of imaging evidence of CPPD disease is estimated to be about 10% in middle-aged adults, depending on articular location, with prevalence increasing to approximately 30% in adults over 80 years of age. CPPD disease is also associated with cartilage degradation and osteoarthritis, although it remains unclear whether CPPD disease is a cause or consequence of these conditions.

Acute CPP crystal arthritis, historically called “pseudogout,” is the most widely recognized form of CPPD disease. It results from CPP crystals in the joint activating pro-inflammatory pathways, leading to IL-1b secretion and causing acute inflammatory arthritis. Chondrocalcinosis, a radiographic finding that is most often due to CPPD, is common in older adults and doubles in prevalence with each decade beyond age 60.

The current research entailed a GWAS in which all genes in the human genome were simultaneously assessed for association with CPPD disease. The study was carried out in the Million Veterans Program, comprising more than 550,000 Veterans (91% male) of African and European genetic ancestry drawn from the US Veterans Health Administration. The main finding was the identification of two genes, RNF144B and ENPP1, that cause CPPD disease in Americans. Importantly, the same genes were detected in both people of European ancestry and African ancestry.

Lead investigator Tony R. Merriman, PhD, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham; Birmingham Department of Veterans Affairs Health Care System; and Department of Microbiology and Immunology, University of Otago (Dunedin, New Zealand), says, "The most significant result of our research was the discovery of one of the genes, ENPP1. The protein encoded by this gene controls the production of chemicals (adenosine monophosphate and inorganic pyrophosphate) that, together with calcium ions, lead to the formation of the CPP crystals."

Co-investigator Sara K. Tedeschi, MD, MPH, Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, and Harvard Medical School, Boston, adds, "The genome-wide association with ENPP1 is particularly exciting to me as a rheumatologist because it makes sense: ENPP1 generates inorganic pyrophosphate, one of the components of CPP crystals. Patients with CPPD disease are desperate for an effective treatment, and trials testing ENPP1 inhibitors in CPPD disease would be of great interest."

Little is known about the other gene, RNF144B, aside from that it is possibly involved in inflammation. More is known about ENPP1 and, of potential importance to people with CPPD disease, drugs targeting the protein have been developed in the treatment of infectious disease and cancer that could be evaluated for the treatment of CPPD disease.

Josef Smolen, MD, Medical University of Vienna (Austria), and Editor-in-Chief of the Annals of the Rheumatic Diseases, comments, "There is a considerable unmet need for treatment of CPPD disease, which commonly focuses on the alleviation of inflammation, most often with non-steroidal anti-inflammatory drugs colchicine or prednisone. This first GWAS study in CPPD disease points to two targets for future treatment, which is crucial given the current lack of options for patients."

Dr. Merriman concludes, "We are thrilled about the potential impact of what we have uncovered in our research and the possibility of new drugs being developed for the treatment of CPPD disease. The findings of this study produced a ‘eureka moment,’ which can be rare in a scientist’s career."

Notes for editors

The article is “Genome-wide association study in chondrocalcinosis reveals ENPP1 as a candidate therapeutic target in calcium pyrophosphate deposition disease,” by Riku Takei, Ann Rosenthal, Tristan Pascart, Richard J. Reynolds, Tuhina Neogi, Robert Terkeltaub, Sara K. Tedeschi, and Tony R. Merriman (https://doi.org/10.1016/j.ard.2025.04.002 opens in new tab/window). It appears in the Annals of the Rheumatic Diseases, volume 84, issue 6 (June 2025), published by Elsevier.

The article is openly available for 60 days at https://ard.eular.org/article/S0003-4967(25)00891-X/fulltext opens in new tab/window.

Full text of this article is also available to credentialed journalists upon request; contact Eileen Leahy at +1 732 406 1313 or [email protected] opens in new tab/window. Journalists wishing to interview the authors should contact Ellie Rowley, University of Otago Communications, at [email protected] opens in new tab/window.

The authors thank Million Veterans Program participants for their service and their continued contributions to the United States through participation in this study. They thank the Million Veteran Program, Office of Research and Development, and Veterans Health Administration for supporting the work.

This work was supported by the United States Department of Veteran's Affairs Merit Review I01 BX004454, Rheumatology Research Foundation Career Development Bridge Funding Award, and National Institutes of Health (NIH), National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) grants P30 AR072571 and K24 AR070892.

About Annals of the Rheumatic Diseases (ARD)

Annals of the Rheumatic Diseases opens in new tab/window (ARD), an official journal of EULAR opens in new tab/window, is an international peer reviewed journal committed to promoting the highest standards of scientific exchange and education. It is the leading rheumatology journal publishing a combination of high-quality scientific papers, including original research, reviews, recommendations, viewpoints, and more. Clinical, basic, and translational science across the inflammatory and non-inflammatory musculoskeletal conditions are part and parcel of this spectrum.

About EULAR

EULAR opens in new tab/window is the European umbrella organization representing scientific societies, health professional associations, and organizations for people with rheumatic and musculoskeletal diseases (RMDs). EULAR aims to reduce the impact of RMDs on individuals and society, as well as improve RMD treatments, prevention, and rehabilitation. To this end, EULAR fosters excellence in rheumatology education and research, promotes the translation of research advances into daily care, and advocates for the recognition of the needs of those living with RMDs by EU institutions.

About Elsevier

A global leader in advanced information and decision support, Elsevier helps to advance science and healthcare, to advance human progress. We do this by facilitating insights and critical decision-making with innovative solutions based on trusted, evidence-based content and advanced AI-enabled digital technologies.

We have supported the work of our research and healthcare communities for more than 140 years. Our 9,700 employees around the world, including 2,300 technologists, are dedicated to supporting researchers, librarians, academic leaders, funders, governments, R&D-intensive companies, doctors, nurses, future healthcare professionals and educators in their critical work. Our 3,000 scientific journals and iconic reference books include the foremost titles in their fields, including Cell Press, The Lancet and Gray’s Anatomy. Together with the Elsevier Foundation opens in new tab/window, we work in partnership with the communities we serve to advance inclusion in science, research and healthcare in developing countries and around the world.

Elsevier is part of RELX opens in new tab/window, a global provider of information-based analytics and decision tools for professional and business customers. For more information on our work, digital solutions and content, visit www.elsevier.com.